Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Biomarker & Immune checkpoint inhibitors (ICIs)

Navigation

Contents

Cancer immunotherapy with checkpoint blockade is now a standard treatment for many cancers, but predictive biomarkers are still needed. Emerging evidence suggests the host microbiome may predict immunotherapy response, though the ideal microbiome is not yet defined.
Malczewski et al. 2020

see also:
Akkermansia muciniphila & Anti-PD-1 antibodies / PD-1 inhibitors
Cancer Immunotherapy / Immuno-Oncology & Gut microbiota
Circulating tumor DNA (ctDNA) & Immune checkpoint inhibitors (ICIs)
Gut microbiota & Immune Checkpoint Inhibitors (ICIs)

References (Sources)

Analysis of Immune Signatures in Longitudinal Tumor samples Yields Insight into Biomarkers of response and Mechanisms of Resistance to Immune Checkpoint Blockade
Chen et al. 2016a Cancer Discov 6: 827-837
Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab
Berman et al. 2009 J Clin Oncol 27:15s (suppl. abstract 3020)
Biomarkers for immunotherapy for treatment of glioblastoma
Lynes et al. 2020
Review
Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy
Failing et al. 2019
Review
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
Feng et al. 2020
Host circulating biomarkers for immune-checkpoint inhibitors: single-agent and combinations
Riudavets et al. 2020 Future Oncology 16: 1665–1668
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
Derosa et al. 2022 Nat. Med. 28: 315-324
Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma
Mourah et al. 2020 Current Opinion in Oncology. 32(2): 91-97
Review
Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy
Malczewski et al. 2020
Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer
Rossi et al. 2020 Immunotherapy 12: 715-724

0-10 / 18

AI Chat

11/5/2026

Chat with our artificial intelligence: